Canada markets close in 1 hour 28 minutes

ALX Oncology Holdings Inc. (ALXO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
14.49-1.92 (-11.68%)
As of 02:31PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close16.41
Open16.17
Bid14.36 x 1800
Ask14.41 x 800
Day's Range14.03 - 16.17
52 Week Range3.94 - 17.42
Volume494,886
Avg. Volume455,385
Market Cap722.029M
Beta (5Y Monthly)1.65
PE Ratio (TTM)N/A
EPS (TTM)-3.57
Earnings DateMar 07, 2024 - Mar 11, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.92
  • GlobeNewswire

    ALX Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, announced today that Jason Lettmann, Chief Executive Officer of ALX Oncology, will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on January 8th -11th, 2024. Mr. Lettmann’s presentation will take place on Mond

  • GlobeNewswire

    ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update

    SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update. Third Quarter 2023 Highlights and Recent Developments Reported positive interim Phase 2 ASPEN-06 clinical trial results for evorpacept for the treatme

  • GlobeNewswire

    ALX Oncology Announces November Investor Conference Participation

    SOUTH SAN FRANCISCO, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that management will participate in three upcoming investor conferences in November. 2023 UBS BioPharma ConferenceFormat: Fireside chat with analyst, Dr. Colin BristowDate: Wednesday, November 8thTime: 1:30 PM ESTLocation: Miami Beach, FLWebcast link: Availa